Physician profile
Anne Greer
NPI 1194422477
$3,745.15
in general payments reported to CMS, 2019-2025
22 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $880 · 2024: $1,650 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,700 · Education: $45.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,700.06 |
| Education | $45.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.69 | 2023-2025 | |
| Ardelyx, INC. | $482.44 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $450.07 | 2024-2025 | Voquezna |
| Genzyme Corporation | $448.94 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.66 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $208.34 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $206.71 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $159.02 | 2024-2025 | Dupixent |
| Celgene Corporation | $157.01 | 2023-2024 | Zeposia |
| Pfizer INC. | $125.64 | 2023-2024 | |
| Lilly USA, LLC | $102.43 | 2024 | Omvoh |
| Celltrion USA INC. | $85.23 | 2024 | Zymfentra, Vegzelma |
| Evoke Pharma, INC. | $63.08 | 2024 | |
| Novo Nordisk INC | $49.29 | 2023-2024 | Wegovy |
| Redhill Biopharma INC. | $47.42 | 2023 | Talicia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.13 | 2024 | Dificid |
| Braintree Laboratories, INC. | $27.80 | 2024 | Suflave |
| Exact Sciences Corporation | $22.83 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $21.57 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $16.77 | 2024 | Resmetirom |
| Echosens North America, INC. | $15.10 | 2024 | Fibroscan |
| W. L. Gore & Associates, INC. | $13.98 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.